Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 10;4(3):58-69.
doi: 10.5306/wjco.v4.i3.58.

Role of E3 ubiquitin ligases in lung cancer

Affiliations

Role of E3 ubiquitin ligases in lung cancer

Barbara C Snoek et al. World J Clin Oncol. .

Abstract

E3 ubiquitin ligases are a large family of proteins that catalyze the ubiquitination of many protein substrates for targeted degradation by the 26S proteasome. Therefore, E3 ubiquitin ligases play an essential role in a variety of biological processes including cell cycle regulation, proliferation and apoptosis. E3 ubiquitin ligases are often found overexpressed in human cancers, including lung cancer, and their deregulation has been shown to contribute to cancer development. However, the lack of specific inhibitors in clinical trials is a major issue in targeting E3 ubiquitin ligases with currently only one E3 ubiquitin ligase inhibitor being tested in the clinical setting. In this review, we focus on E3 ubiquitin ligases that have been found deregulated in lung cancer. Furthermore, we discuss the processes in which they are involved and evaluate them as potential anti-cancer targets. By better understanding the mechanisms by which E3 ubiquitin ligases regulate biological processes and their exact role in carcinogenesis, we can improve the development of specific E3 ubiquitin ligase inhibitors and pave the way for novel treatment strategies for cancer patients.

Keywords: Apoptosis; Bortezomib; DNA repair; E3 ubiquitin ligases; Gene regulation; Lung cancer; Proteasome inhibitors; Ubiquitin-proteasome system.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ubiquitin molecules are covalently conjugated to targeted proteins in a three-step enzymatic cascade. First, an E1 ubiquitin-activating enzyme activates ubiquitin in an adenosine triphosphate (ATP)-dependent manner. Activated ubiquitin is then transferred to the E1 enzyme, followed by the transfer of ubiquitin to an E2 ubiquitin-conjugating enzyme. Finally, an E3 ubiquitin protein ligase recognizes the target proteins and mediates the conjugation of one or more ubiquitin molecules to a lysine residue on the targeted proteins. Really interesting new gene (RING) E3 ubiquitin ligases mediate the direct transfer of ubiquitin from E2 to the targeted substrate whereas Homologous to the E6-associated protein (E6-AP) carboxyl terminus (HECT) E3 ubiquitin ligases first interact with the cognate E2, followed by linkage with ubiquitin and subsequent transfer of ubiquitin to the targeted substrate. AMP: Adenosine monophosphate.

References

    1. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications. J Cell Biochem Suppl. 2000;34:40–51. - PubMed
    1. Christian PA, Fiandalo MV, Schwarze SR. Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH. Mol Cancer. 2011;10:57. - PMC - PubMed
    1. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458:438–444. - PubMed
    1. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776–4789. - PubMed
    1. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–381. - PubMed

LinkOut - more resources